Accuray (ARAY)
(Delayed Data from NSDQ)
$1.91 USD
+0.14 (7.91%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.92 +0.01 (0.52%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.91 USD
+0.14 (7.91%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.92 +0.01 (0.52%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Zacks News
Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up
by Zacks Equity Research
Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.
Quest Diagnostics (DGX) Tops Q4 Earnings, 2018 View Strong
by Zacks Equity Research
Quest Diagnostics' (DGX) year-over-year revenue improvement in Q4 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.
Boston Scientific (BSX) Q4 Earnings In Line, Revenues Top
by Zacks Equity Research
In Q4, Boston Scientific (BSX) registers balanced growth across all business lines and geographies.
Conmed (CNMD) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Conmed (CNMD) benefits from impressive general surgery performance and enhanced innovation in Q4.
McKesson (MCK) Beats on Q3 Earnings & Revenues, Ups '18 View
by Zacks Equity Research
Strong Performance in Distribution Solutions segment drives McKesson (MCK) in Q3. An impressive FY18 outlook instills investor's optimism.
Baxter (BAX) Beats on Q4 Earnings & Revenues, '18 View Solid
by Zacks Equity Research
Strong performance in the Hospital Products and Renal Products segments drives Baxter (BAX) in Q4.
IDEXX Laboratories (IDXX) Beats on Q4 Earnings and Revenues
by Zacks Equity Research
IDEXX (IDXX) rides high on strength in CAG business in Q4. A raised guidance buoys optimism.
4 Reasons Why You Should Buy Accuray (ARAY) Stock Right Now
by Zacks Equity Research
Accuray (ARAY) rides high on its Radixact platform and latest software overhaul.
Zacks.com highlights: Accuray, Berkshire Hills Bancorp, A. Schulman, Sysco and Tailored Brands
by Zacks Equity Research
Zacks.com highlights: Accuray, Berkshire Hills Bancorp, A. Schulman, Sysco and Tailored Brands
QIAGEN (QGEN) Beats on Q4 Earnings and Revenues, Issues View
by Zacks Equity Research
QIAGEN's (QGEN) year-over-year growth in Q4 revenues is encouraging. Expansion in operating margin buoys optimism.
Thermo Fisher (TMO) Q4 Earnings Beat on Growth in All Lines
by Zacks Equity Research
Thermo Fisher (TMO) registers a solid international performance in Q4 with strong year-over-year growth in the Asia-Pacific and the emerging markets of China, South Korea and the Middle East.
Stryker (SYK) Beats Earnings and Revenue Estimates in Q4
by Zacks Equity Research
Stryker's (SYK) Q4 results benefit from Mako product platform and higher organic sales.
Illumina (ILMN) Tops Q4 Earnings & Revenues, Issues Guidance
by Zacks Equity Research
Illumina (ILMN) gains from strength in sequencing consumables and instruments as well as microarray portfolios in Q4.
Align Technology (ALGN) Q4 Earnings Top on Invisalign Sales
by Zacks Equity Research
Align Technology (ALGN) gains on solid contributions from the Clear Aligner as well as Scanner and Service segments in Q4.
Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Sales Beat (Revised)
by Zacks Equity Research
Zimmer Biomet (ZBH) rides high on Hip and S.E.T segments in Q4.
Hill-Rom (HRC) Beats Q1 Earnings and Revenues, Margins Up
by Zacks Equity Research
Hill-Rom (HRC) rides on strength in Front Line Care and Surgical Solutions segments in Q1.
Abaxis (ABAX) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Abaxis (ABAX) Q3 earnings gain on strength in Medical and Veterinary segments.
Accuray (ARAY) Q2 Loss Narrower Than Estimates, Revenues Top
by Zacks Equity Research
Radixact System and major software overhaul drive Accuray (ARAY) in Q2.
Varian Gains Ground on New Applications, Grows in Australia
by Zacks Equity Research
Varian's (VAR) innovative product pipeline will continue to drive growth over the long term.
Varian to Open Facility in Brazil, Global Growth in Focus
by Zacks Equity Research
Varian's (VAR) strong overseas presence is likely to fortify its foothold in the emerging markets. The recent initiative would boost its presence in Latin America.
Accuray's (ARAY) Q1 Loss in Line, Revenues Beat Estimates
by Zacks Equity Research
Accuray (ARAY) rides high on its product and service segments in Q1.
Why Is Accuray (ARAY) Up 9.9% Since the Last Earnings Report?
by Zacks Equity Research
Accuray (ARAY) reported earnings about 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Accuray (ARAY) Grapples With Falling Margin and Product Mix
by Zacks Equity Research
Accuray Inc.'s (ARAY) low product margins and unfavorable product mix will continue to be a drag on the company's performance.
Accuray (ARAY) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Accuray's (ARAY) new TomoTherapy product platform, also known as Radixact, continues to contribute to the top line. Solid Fiscal 2018 guidance instills investor confidence.
Accuray's Radixact Now Used by Boise Summit Cancer Center
by Zacks Equity Research
Accuray's (ARAY) Radixact system leverages on its flagship TomoTherapy platform. The company's top-line growth is dependent on TomoTherapy system sales.